{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
telotristat ethyl
to a specific field?
Status:
Investigational
Source:
NCT04551118: Not Applicable Interventional Completed Healthy
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:gapromidine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:metofenazate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Metofenazate is a calmodulin inhibitor and was studied as an antipsychotic drug.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Tibalosin is a phenylethylamine derivative patented by Continental Pharma as a potent vasodilator. Tibalosine interacts specifically with alpha- and beta-adrenergic receptors and calcium channel binding sites. In preclinical models, Tibalosin exerts favor influences on arterial pressure in the hypertensive animal. The drug has acceptable toxicity in experimental animals and has been well tolerated by normal human subjects in daily doses of up to 200 mg.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Etiracetam is a nootropic agent. (-)-(S) enantiomer of etiracetam levetiracetam (Keppra®) is used for the treatment of epilepsy.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ACHIRAL)
Guanclofine was studied as an adrenergic neuron blocking agent.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
AstraZeneca R&D Charnwood (formerly Astra Charnwood, a subsidiary of AstraZeneca) was developing sibenadet (Viozan, AR-C68397AA) for the potential treatment of chronic obstructive pulmonary disease and asthma. Sibenadet is a dual D2 dopamine receptor, beta2-adrenoceptor agonist that combines bronchodilator activity with the sensory afferent modulating effects associated with D2-receptor agonism. Development of sibenadet has been discontinued due to disappointing efficacy findings.
Status:
Investigational
Source:
USAN:DITIOCADE SODIUM [USAN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01904487: Phase 1 Interventional Completed Alcoholism
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
